Effective in vitro evaluation of the risk of histamine release related to valemetostat tosylate using MRGPRX2-expressing cells

Mas-related G-protein-coupled receptor X2 (MRGPRX2), expressed on mast cells, is associated with drug-induced pseudo-allergic reactions. Although it is well known that there are differences of sensitivity between species in the pseudo-allergic reactions, no platform for evaluating a human risk of th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of toxicological sciences 2024, Vol.49(4), pp.163-174
Main Authors: Hamamura-Yasuno, Eri, Kinoshita, Junzo, Goto, Koichi, Fujimoto, Kazunori, Pignatello, Michael, Tsuchiya, Yoshimi, Mori, Kazuhiko
Format: Article
Language:English
Subjects:
Allergic reactions
Allergies
Antineoplastic drugs
Cell activation
Dogs
G protein-coupled receptors
Histamine
Histamine release
Human risk assessment
Laboratory animal
Mast cell
Mast cells
MRGPRX2
Pseudo-allergic reaction
Risk assessment
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mas-related G-protein-coupled receptor X2 (MRGPRX2), expressed on mast cells, is associated with drug-induced pseudo-allergic reactions. Although it is well known that there are differences of sensitivity between species in the pseudo-allergic reactions, no platform for evaluating a human risk of the pseudo-allergic reactions observed in nonclinical studies has been established. Valemetostat tosylate, developed as an anti-cancer drug, induced histamine release in a nonclinical study with dogs. The purpose of the current study was to identify the mechanism and assess the human risk of valemetostat-tosylate-induced histamine release using dog and human MRGPRX2-expressing cells. In an experiment with human or dog MRGPRX2-expressing cells, valemetostat tosylate caused activation of human and dog MRGPRX2. Importantly, the EC50 for dog MRGPRX2 was consistent with the Cmax value at which histamine release was observed in dogs. Furthermore, the EC50 for human MRGPRX2 was ca. 27-fold higher than that for dog MRGPRX2, indicating a species difference in histamine-releasing activity. In a clinical trial, histamine release was not observed in patients receiving valemetostat tosylate. In conclusion, an in vitro assay using human and animal MRGPRX2-expressing cells would be an effective platform to investigate the mechanism and predict the human risk of histamine release observed in nonclinical studies.
ISSN:0388-1350
1880-3989
DOI:10.2131/jts.49.163